NasdaqGS:DFTXPharmaceuticals
How Definium’s Widening 2025 Loss Will Impact Definium Therapeutics (DFTX) Investors
Definium Therapeutics, Inc. reported full-year 2025 results on February 26, 2026, posting a net loss of US$183.79 million and a basic loss per share from continuing operations of US$2.06, both higher than the prior year.
The widening loss highlights the financial strain of Definium’s development efforts even as it maintains visibility with investors through events like the TD Cowen Health Care Conference in Boston.
We’ll now examine how this increased net loss shapes Definium Therapeutics’...